Channel Synergy Now under OraSure Technologies, Sherlock can leverage OraSure’s extensive point-of-need and home diagnostic channels to accelerate market access for CRISPR-based diagnostics across clinics, hospitals, and consumer settings.

Public Private Partnerships The company’s SBIR, USDA, and academic collaborations (e.g., GMGI) highlight a strong pipeline for government-funded diagnostic programs, offering sales opportunities to government labs, universities, and non-profit health initiatives seeking advanced CRISPR assays.

Manufacturing Capacity A new UK biomanufacturing facility and related funding indicate scalable production capabilities, enabling partnerships for contract manufacturing, OEM kit production, or regional supply agreements in Europe and beyond.

Platform Ecosystem An AI-powered operating system for CRISPR diagnostics and a broad software stack open doors to services around platform onboarding, data analytics, and workflow integration for customers deploying Sherlock tests within existing lab or clinical IT environments.

Market Expansion The focus on democratized testing points to growth in consumer/home testing, telemedicine-enabled diagnostics, and adjacent markets; explore retail and e-commerce partnerships leveraging tech stack (Shopify) to reach broader end users and clinics via partner networks.